AvePoint enters the post-earnings week with analysts moving higher on the stock even as the price slipped — a divergence that captures the central tension around this application software name right now.
The company reported on August 6 and the stock fell 4.6% on the day, closing around $12.79. That reaction sits at odds with the analyst community's response: both TD Cowen and Evercore ISI raised their price targets on August 7, the morning after results. TD Cowen's Derrick Wood lifted his target from $14 to $15 while holding a Buy rating; Kirk Materne at Evercore moved from $14 to $16, maintaining Outperform. The consensus mean target now runs near $16.36, roughly 28% above where the stock is trading. Eight analysts carry buy-equivalent ratings, and none of the recent post-earnings moves were downgrades. The Street's message is that the selloff was a buying opportunity, not a confirmation of the bear case.
The bear case itself is worth unpacking. Bulls point to ARR growth potential running above 25% on an FX-adjusted basis, a broadening customer base, and a management team with a clear roadmap. Bears lean on AvePoint's structural dependency on the Microsoft ecosystem and the risk that margin estimates get trimmed as the company invests to compete. DA Davidson maintains an $18 target — the most bullish on the Street — while Scotiabank is the lone voice carrying a lower $12 target, essentially at current levels. Citigroup sits at Neutral with a $13 target, meaning the two sceptics are clustered near where the stock trades, while the eight bulls project meaningful upside. Valuation multiples have eased: EV/EBITDA has compressed by roughly 1.8x over the past 30 days to 20.7x, which is a more comfortable entry level than a month ago.
Positioning in the lending market is about as loose as it gets. Availability for AVPT borrows is running near 5,900% of short interest — meaning there are roughly 60 shares available to lend for every share currently shorted. That figure has risen sharply this week, up more than 37% from last week's levels. Cost to borrow is a negligible 0.55%, down 13% on the week despite a 34% rise versus a month ago, and even that month-on-month move leaves it firmly in "easy borrow" territory. Short interest at 5.8% of the free float is the one number worth noting, but the week-on-week change is less than 0.4% and the borrow market is nowhere near stressed. The SI history shows a notable step-down from the mid-July range of ~15.9 million shares to the current ~12.6 million — a large block of shorts covered in late July — and the level has been stable since. The ORTEX short score sits at 49.4, effectively neutral, consistent with a market that isn't loading up or covering in a hurry.
Options positioning is emphatically bullish in structure. The put/call ratio is running at 0.093, almost indistinguishable from its 20-day average of 0.094 and only a z-score of -0.09 from the mean — but the striking detail is the absolute level. A PCR below 0.10 means roughly one put for every ten calls. The 52-week low for the PCR is 0.025 and the high is 0.71, so the current reading sits in deeply call-heavy territory. Options traders are not hedging this name; they are positioned for upside, and that has been a persistent feature for weeks.
Insider activity provides a mild counterpoint. The Chief Legal Officer, Brian Brown, sold just under 50,000 shares across four transactions between July 14 and July 29, raising roughly $656,000 in total at prices between $13.00 and $13.18. These are modest in scale and carry low significance scores. CEO Tianyi Jiang and CFO James Caci both sold small parcels on June 12 at $10.87 — well below current levels — which in retrospect looks like routine plan-driven activity rather than a directional call. The 90-day net insider position is actually slightly positive at around 92,000 shares, softening the read on any single executive's disposals.
Among peers, SPT surged 26% on the day and 20% on the week — a dramatic outlier. DBX gained 6.9% on the week and BOX added 5.4%, while WEAV dropped 19% after its own results. AVPT's 1.8% weekly decline therefore looks modest relative to the peer range. The next earnings event is not until November 5, so the short-term catalyst calendar is clear — making the pace of analyst target revisions and any ARR update commentary the main things to track between now and then.
See the live data behind this article on ORTEX.
Open AVPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
